Neuro-Oncology

Papers
(The H4-Index of Neuro-Oncology is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Motor Seizures Confer Overall Survival Benefit in WHO Grade 2 Glioma1420
A Retrospective Review of the Clinical Outcomes of Lung Cancer Patients Referred into the Regional Neuro-Oncology Pathway in 2020 in Merseyside, United Kingdom994
Extent of MGMT Promoter Methylation Modifies the Effect of Temozolomide on Overall Survival in Patients with Glioblastoma: A Regional Cohort Study470
P02.11.B An hypothesis generating study of MRI-Derived Radiomics on tumor and microenvironment tissue heterogeneity to guide post-operative management of glioblastoma: toward personalized radiation tr341
JS09.7.A Reirradiation for recurrent high grade glioma (HGG) patients: results of a single arm prospective phase 2 study289
P11.39.B An unusual case of astroblastoma in adult: a case report and review of the literature222
P01.08.A Perioperative Levetiracetam for seizure prophylaxis in seizure naive brain tumor patients with focus on neurocognitive functioning146
P12.15.B Astrocyte immunometabolic regulation of the glioblastoma microenvironment drives tumor pathogenicity143
P11.36.A Could a transcriptome profile predict local control for glioblastoma?132
P18.10.B Natural history of meningiomas - a serial volumetric analysis of 240 tumors110
P06.05.A Repeated intracranial administration of ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB): A multi-cohort adaptive phase I clinical trial106
OS08.7.A Lomustine and the immunocytokine L19TNF are a promising treatment combination for recurrent glioblastoma101
LGG-24. DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR MANAGEMENT AND OUTCOME: A SINGLE CENTER EXPERIENCE97
HGG-20. NOVEL PAEDIATRIC CASE OF A SPINAL HIGH-GRADE ASTROCYTOMA WITH PILOID FEATURES IN A PATIENT WITH NOONAN SYNDROME97
DIPG-37. TRANSCRIPTIONAL, EPIGENETIC, AND IMMUNOLOGICAL FEATURES OF PAEDIATRIC-TYPE H3 K27-ALTERED DIFFUSE MIDLINE GLIOMAS ORIGINATING FROM DIFFERENT BRAIN LOCATIONS97
CTIM-25. NEOADJUVANT ANTI-PD1 IMMUNOTHERAPY FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES OF A STAGE 2 SINGLE-ARM EXPANSION COHORT97
MDB-39. ASSESSMENT OF MEDULLOBLASTOMA PATIENTS THROUGH MONITORING EXTRACELLULAR VESICLES VIA SURFACE-ENHANCED RAMAN SPECTROSCOPY COMBINED WITH MACHINE LEARNING96
MODELLING GBM RECURRENCE: THE INflUENCE OF PERI-LESIONAL OEDEMA AND THE DISCONNECTOME93
NCMP-01. CEREBRAL ANGIOSARCOMA AND DISTANT RADIATION THERAPY85
P11.61.B TUMOR ASSOCIATED EPILEPSY AND RESTRICTION OF DRIVING PRIVILEGES IN THE FIRST YEAR AFTER BRAIN TUMOR SURGERY80
P20.15.A DESCRIPTIVE ANALYSIS OF A SERIES OF H3 K27-ALTERED DIFFUSE MIDLINE GLIOMAS IN CHILDREN AND ADULT POPULATION77
Ongoing expansion of journal activities to meet the needs of stakeholders73
P11.55.B ROLE OF FRAILTY IN THE MANAGEMENT OF PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE MULTICENTER STUDY73
P16.06.A INCIDENCE, FOLLOW UP AND OUTCOME IN INCIDENTAL MENINGIOMA IN THE GOTHENBURG REGION - WHAT HAS HAPPENED IN 10 YEARS?72
P03.05.B PRIMARY GAMMA KNIFE RADIOSURGERY FOR PINEAL REGION TUMORS, A SYSTEMATIC REVIEW AND POOLED ANALYSIS OF AVAILABLE LITERATURE WITH HISTOLOGICAL STRATIFICATION69
P07.03.A COMPLETE LONG-LASTING RESPONSE TO MULTIMODAL THIRD LINE TREATMENT WITH NEUROSURGICAL RESECTION, CARMUSTINE WAFER IMPLANTATION AND DABRAFENIB PLUS TRAMETINIB IN A BRAFV600E MUTATED HIGH-GRADE 68
OS05.6.A TELEMEDICINE IN NEURO-ONCOLOGY - AN EVALUATION OF REMOTE CONSULTATIONS DURING THE COVID-19 PANDEMIC67
P19.04.B EXAMINATION OF THE ROLES OF KDM6A AND KDM6B HISTONE DEMETHYLASES IN ISOCITRATE DEHYDROGENASE (IDH) MUTANT GLIOMA66
P10.06.B APPLYING TUMOR TREATING FIELDS (TTFIELDS) FOR ENHANCEMENT OF TEMOZOLOMIDE AND LOMUSTINE EFFICACY IN GLIOBLASTOMA CELL LINES66
P11.10.B USEFULNESS OF PHOTODYNAMIC THERAPY (PDT) WITH TALAPORFIN SODIUM FOR GLIOBLASTOMA65
P07.15.B NEUROMUSCULAR HIGH-RESOLUTION ULTRASOUND IN PERIPHERAL NEUROTOXICITY OF SYSTEMICALLY TREATED CANCER PATIENTS65
TARGETING RESIDUAL CANCER FROM THE INVASIVE MARGIN OF GLIOBLASTOMA USING COMPUTATIONAL TOOLKITS64
IMAGING HABITAT CHANGES AFTER PREOPERATIVE RADIOTHERAPY FOR GLIOBLASTOMA: UTILISATION OF A BIOINFORMATICS AND MACHINE LEARNING PIPELINE TO CHARACTERISE REGIONAL TREATMENT RESPONSE64
AN EVALUATION OF THE USE OF TARGETED GENE PANELS TO IDENTIFY TARGETED TREATMENTS IN PATIENTS WITH BRAIN TUMOURS63
BIOPSY VS BEST SUPPORTIVE CARE IN GLIOBLASTOMA: IMPACT OF NO POST-OP RADIOTHERAPY ON OVERALL SURVIVAL63
IMMU-18. ENHANCING GD2.CAR T CELL THERAPY FOR DIFFUSE MIDLINE GLIOMA WITH LSD1 AND HDAC INHIBITORS59
LGG-13. UNRAVELING THE SPATIAL TUMOR MICROENVIRONMENT OF PEDIATRIC LOW-GRADE GLIOMAS USING IMAGING MASS CYTOMETRY59
HGG-43. DIFFUSE PEDIATRIC HIGH GRADE GLIOMA SUCCESSFULLY TREATED WITH MULTIMODAL THERAPY59
THE LINK BETWEEN M6A RNA METHYLATION AND R LOOPS IN PAEDIATRIC HIGH-GRADE GLIOMAS AND EPENDYMOMAS59
MDB-14. TREATMENT AND OUTCOMES OF MEDULLOBLASTOMA: FIRST REPORT FROM ARMENIA58
LMIC-08. NEUROSURGERY UTILIZATION RATE FOR PEDIATRIC LOW-GRADE GLIOMA: A SIMULATION-BASED ANALYSIS56
RADT-06. ENCOURAGING OUTCOMES AFTER CRANIO-SPINAL IRRADIATION (CSI) WITH MODERN IMAGE GUIDED INTENSITY MODULATED PROTON THERAPY (IMPT) (IMPT-CSI) IN CHILDREN AND YOUNG ADULTS (AYA)- AN INSTITUTION EXP55
DIPG-39. ONCOHISTONE H3.3K27M-DRIVEN CREB5/ID1 AXIS DICTATES THE MALIGNANT CELL STATES OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)54
HGG-03. TRUNCATING MUTATIONS IN PPM1D COOPERATE WITH PI3K ALTERATIONS TO DRIVE PEDIATRIC DIFFUSE MIDLINE GLIOMAS54
QOL-01. FEASIBILITY AND EFFICACY OF DIETARY AND LIFESTYLE INTERVENTIONS FOR HYPOTHALAMIC OBESITY DURING CHILDHOOD: A SYSTEMATIC REVIEW53
IMMU-20. INNATE IMMUNE EVASION IN MYC-AMPLIFIED MEDULLOBLASTOMA53
DIPG-27. MATCHED PRIMARY-RELAPSE PEDHGG PATIENT-DERIVED XENOGRAFT MODELS TO IDENTIFY THERAPY RESISTANCE PROFILES52
DIPG-86. INVESTIGATING THE TUMOR ENVIRONMENT AND SIGNALING DEPENDENCIES DRIVING DIFFUSE MIDLINE GLIOMA TUMOR INITIATION, PROGRESSION, AND RESISTANCE: A COMPREHENSIVE APPROACH LEVERAGING BULK MULTIOMIC51
DIPG-85. MALT1 IN H3K27-ALTERED DIFFUSE MIDLINE GLIOMA51
MDB-62. SUBGROUP AND SUBTYPE-SPECIFIC OUTCOMES IN METASTATIC INFANT MEDULLOBLASTOMA49
0.18576002120972